ANNOUNCE 2: A phase Ib (open label)/Phase II (only) randomized, double-blinded study evaluating the efficacy of Gemcitabine and Docetaxel with or without a human Anti-PDGFRa Monoclonal Antibody (Olaratumab) in the Treatment of Advanced Soft Tissue Sarcoma (Academic)

Bone Sarcoma CTC study: Optimisation of circulating tumour cell detection in bone sarcomas

CaboGIST EORTC 1317:  Phase II study of cabozantinib in patients with metastatic gastrointestinal stromal tumour (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and suntinib

ESPRIT: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma

EE 2012 - an international randomised controlled trial for the treatment of newly diagnosed Ewing's sarcoma family of tumours

EZH202 - A phase II, multicentre study of the EZH202 Inhibitor Tazemetostat in adult subjects with INI1-Negative tumours or relapsed refractory Synovial and Epitheliod type.

HGUS EORTC 62113 : A randomised double-blind phase II study evaluating the role of maintenance cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) or response to doxorubicin +/-ifosfamide or in metastatic first line treatment

HOPE: Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults withOsteosarcoma

IMRIS: A phase II study of intensity modulated radiotherapy (IMRT) in primary bone and soft tissue sarcoma

Kindred Study: The International Sarcoma Kindred Study: a global multi-site prospective cancer genetics study

RAPPER: Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy

rEECUr: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma

SSG XXII: A phase III prospective, multi-centre, open-label, 2 arm study for evaluation of 2 durations of adjuvant treatment with the tyrosine kinase inhibitor imastinib mesylate of operable gastrointestinal stromal cells tumour (GIST) with a high risk for recurrence

 

Sometimes there may be other trials open - it is always worth asking your doctor.